Digital health is entering a more mature phase in 2026 as consolidation accelerates through targeted M&A, driven by the need for scale, artificial intelligence and pressure from payers, investors say. The post The Digital Health M&A Wave Is Finally Here appeared first on MedCity News.
Epic’s rollout of a built-in AI charting tool is intensifying competition in the already crowded ambient AI scribe market, forcing standalone vendors to sharpen their differentiation in an Epic-dominated health system landscape. The post Do Ambient Scribe Startups Have a Future Now That Epic Launched Its Own Tool? appeared first on MedCity News.
Eikon Therapeutics’ IPO haul will support a lead program that could expand the scope of cancer immunotherapy. Eikon’s stock market debut builds on growing IPO momentum, following upsized offerings from Aktis Oncology and Veradermics. The post Eikon Therapeutics Continues the IPO Parade, Raising $381M for Cancer Drug Clinical Trials appeared first on MedCity News.
The conversation between MedCity News Editor-in-Chief Arundhati Parmar and Samir Batra, managing partner of Health Innovation Pitch, highlighted news from the J.P. Morgan Healthcare Conference, particularly how technology and biopharma companies are shaping AI in healthcare. The post Debunked Episode 23: Companies Vie for Healthcare AI Dominance appeared first on MedCity News.
Confirmed diversion cases do not equal true prevalence – they are directly dependent on investigative proficiency, tooling, and the bandwidth of the teams doing the work. The post The Illusion of Diversion Data: Why Confirmed Diversion Counts Misrepresent True Risk appeared first on MedCity News.
With regulatory scrutiny intensifying and the demand for speed, compliance, and clarity growing, understanding the nuanced differences between AI approaches is essential for payers, providers, and patients alike. The post Choosing the Right Methods for the Right AI to Accelerate Prior Authorizations appeared first on MedCity News.
Jake Leach became DexCom’s chief executive on January 1 and is trying to write the turnaround story of this innovative medtech company. One story to tell is how CGMs should be a no-brainer for type 2 diabetes patients on GLP-1 weight loss drugs. The post DexCom’s CEO Believes Diabetics On GLP-1s Should Also Wear CGMs…
Veradermics’s drug, a pill version of the topical hair loss product minoxidil, was developed with technology intended to avoid the cardiovascular risks associated with oral dosing of this compound. The first of three pivotal clinical trials is expected to yield preliminary data in the first half of 2026. The post Baldness Biotech Veradermics Prices $256M…
Virtual women’s health provider Midi Health has reached unicorn status after raising a $100 million Series D, with investors backing its insurance-covered, direct-to-consumer model. The company is positioning itself as a long-term, virtual “hospital without walls” designed to meet women’s health needs across midlife and beyond. The post Digital Health’s Latest Unicorn: Why Investors Are…
beHuman’s $4 million seed round was led by Santé Ventures, with participation from DHVP.io. It will help expand its footprint. The post Cancer Detection Startup Secures $4M to Expand Access in Underserved Communities appeared first on MedCity News.